| PHA |
Pharming maart 2023
• Pharming Group (NASDAQ:PHAR) is now covered by analysts at Royal Bank of Canada. They set an outperform rating on the stock.The current price is $12.70....
|
sp1946 |
| TOM |
TomTom mei
Nabeurs toch een heel ander verhaal: 7.65 393 18:11:02.000 ? 7.4819 76,586 18:10:31.000 ? 7.4759 18,833 18:10:30.000 ? 7.78 1,134 18:10:01.000 ? 7.4913 245 18:09:02.000 ?...
|
sp1946 |
| STE |
Stern 2022
Weet iemand of van de uitkering van € 14,5 dividendbelasting ( 25% ) ingehouden wordt ?...
|
sp1946 |
| BIO |
abeona therapeutics inc. (ABEO): is de raket gelanceerd?
Abeona to host investor webinar on Tuesday, February 16, 2021 at 1:00 p.m. ESTNeurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s AB...
|
sp1946 |
| ARG |
Argenx stoomt richting eerste medicijn op de markt
Biologics License Application on track to be submitted to U.S. Food and Drug Administration by end of 2020...
|
sp1946 |
| GAL |
Galapagos juli 2020
Number of shares issued at the end of the period 64,819,022Total current financial investments and cash and cash equivalents at the end of the period € 5,722,378.00064 mln aandelen met €...
|
sp1946 |
| GAL |
Galapagos juli 2020
Meer dan $ 100 lager.o GALAPAGOS NV/S (NASDAQ:GLPG) was downgraded by Stifel Nicolaus ( ) (analyst Adam Walsh) from a buy rating to a hold rating. They now have a $...
|
sp1946 |
| BIO |
Poxel
ImegliminImeglimin is the first orally-available anti-diabetes drug candidate that simultaneously targets all three key organs of diabetes, which includes the pancreas, liver, and muscles.Japan/As...
|
sp1946 |
| BIO |
Poxel
• Financing of up to EUR 30 million through a bond loan with IPF Partners • Draw down of the first tranche of EUR 6.5 million expected in November 2019 • Cash balance at year-end 2019 expected to ...
|
sp1946 |
| BIO |
Poxel
Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASH November 08, 2019 • FDA feedback supports plan to advance PXL065 using the 505(b)(2) regulatory pathway for...
|
sp1946 |
| BIO |
Poxel
Maandagmiddag 16.00 uur.• Presentation will include an overview of Poxel’s two clinical-stage programs for the treatment of NASH LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR...
|
sp1946 |
| UNI |
Wat is de waarde van uniQure?
New coverage - healthcareSep. 12, 2019 8:54 AM ET|About: ANI Pharmaceuticals, Inc. (ANIP)|By: Douglas W. House, SA News EditUniQure NV (NASDAQ:QURE) initiated with Buy rating and $67 (41% upside...
|
sp1946 |
| ARG |
ARGEN-X 2019 De nieuwe parel !
Alle biofondsen staan onder druk. Bij de opening was de koers onveranderd en daarna gaat de koers langzaam volgens een vast patroon naar beneden. Kijk naar de daggrafiek. Overigens als er grote tegenv...
|
sp1946 |
| BIO |
Poxel
Komende maandag tijdens de conferentie wat nieuws ??Sumitomo Dainippon Pharma is our development and commercialization partner for Imeglimin for the treatment of type 2 diabetes in Japan, China...
|
sp1946 |
| OXU |
Gaat THROMBO het nu waar maken in 2018
Positive Topline Phase 1 Results with THR-149 (Plasma Kallikrein Inhibitor) for treatment of DMEMixed Topline Results from exploratory THR-317 (anti-PlGF) Phase 2a ranibizumab combination s...
|
sp1946 |
| UNI |
Wat is de waarde van uniQure?
uniQure N.V. (QURE) After Hours TradingQURE $49* 6.98 -12.47%...
|
sp1946 |
| OXU |
Gaat THROMBO het nu waar maken in 2018
Company on Track for Data Read Out by End of 2019Leuven, Belgium, 4 September 2019 – 7.30 AM CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments...
|
sp1946 |
| UNI |
Wat is de waarde van uniQure?
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia BLEXINGTON, Mass. and AMSTERDAM, the Netherlands, S...
|
sp1946 |
| OXU |
Oxurion in 2019
Als de uitkomsten van 149 en 687 tegen waren gevallen hadden zij dat gelijk moeten melden dus ik verwacht beter nieuws dan de tegenvallende resultaten van 187. ...
|
sp1946 |
| OXU |
Oxurion in 2019
Oxurion geeft presentatie op EURETINA 2019Gepubliceerd op 2 sep 2019 om 07:41 | (ABM FN) Oxurion zal een presentatie geven over de uitkomsten van zijn Fase 1 klinische studie met THR-149 bij pa...
|
sp1946 |
| OXU |
Oxurion in 2019
Further preclinical and clinical data presentations of its other diabetic eye disease clinical candidates, THR-687 (Pan-RGD Integrin Inhibitor) and THR-317 (anti-PlGF), will also be delivered...
|
sp1946 |
| BIO |
Poxel
en dat allemaal voor net € 6 euro!!!! Poxel Reports Financial Results for First Half 2019 and Provides Corporate UpdateDOWNLOAD AS PDF August 26, 2019 • Positive Phase 3 top-line resu...
|
sp1946 |
| STE |
Stern 2019
Zien er toch schitterend uit ? Intrinsiek € 28, laat het bod maar komen !!...
|
sp1946 |
| AME |
Viking Therapeutics (VKTX) succes met NASH..?
Initiation of Phase 2b NASH trial planned in 2H19. Pre-IND package submitted for VK2809; Initiation of Phase 2b NASH trial planned in 2H19. The company recently submitted a pre-investigational...
|
sp1946 |
| AME |
Viking Therapeutics (VKTX) succes met NASH..?
Viking Therapeutics (VKTX) are testing medicines known as THR agonists. Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions • ALLISON GATLIN• 8/16/2019The obesity epidem...
|
sp1946 |
| ONX |
Onxeo 2019
HALF-YEAR 2019 HIGHLIGHTS, RECENT DEVELOPMENTS AND OUTLOOK AsiDNA™ - In early January 2019, reporting of the identification of biomarkers predicting the response to AsiDNA™, which could optimize it...
|
sp1946 |
| ONX |
Onxeo 2019
Press release Onxeo Reports Half-Year 2019 Financial Resultsand Provides Business Update • Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile• Init...
|
sp1946 |
| OXU |
Gaat THROMBO het nu waar maken in 2018
en dat voor Pharming op € 2,50, staat er onder. Die koersdoelen zeggen helemaal niets. ...
|
sp1946 |
| OXU |
Gaat THROMBO het nu waar maken in 2018
Ik vind 123.000 in ruim 2 uur ook niet verkeerd....
|
sp1946 |
| ONX |
Onxeo 2019
AsiDNA™ Letter - No. 1The field of DDR and the strategic advantages of AsiDNA™ Ladies, Gentlemen and Shareholders,The clinical development of AsiDNA™ is well on its way and we ...
|
sp1946 |
| ONX |
Onxeo 2019
The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a Buy recommendation Paris (France), July 1st, 2019 – 7:00 a.m. CEST - Onxeo S.A. (Euronext Paris,...
|
sp1946 |
| ONX |
Onxeo 2019
Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase • OX401 is the second candidate utilizing Onxeos proprietary platform of decoy agonists,...
|
sp1946 |
| GEN |
Genfit 2019
June 11, 2019 GENFIT: Cymabay Phase 2 data: read-across for RESOLVE-IT? Dear investor, In reaction to the confusion generated by Cymabays Phase 2b announcement earlier today, wed l...
|
sp1946 |
| OXU |
Gaat THROMBO het nu waar maken in 2018
Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting Leuven, Belgium, 6th June 2019 - 7 PM CET - Oxurion NV...
|
sp1946 |
| BIO |
Poxel
plus 10% vandaag. Er moet iets moois aankomen....
|
sp1946 |
| GEN |
Genfit 2019
Barclays likes Genfit in premarket analyst actionApr. 22, 2019 8:58 AM ET|About: Canopy Growth Corporation (CGC)|By: Douglas W. House, SA News Editor Genfit (NASDAQ:GNFT) initiated with Overweig...
|
sp1946 |
| GEN |
Genfit 2019
GENFIT announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC Lille (France), Cambridge (Massachusetts, United States), April 18, 2019 – GENFIT (Nasdaq and...
|
sp1946 |
| BIO |
NASH - bedrijven
News Release Issued: Apr 11, 2019 (7:02am EDT)SAN DIEGO, April 11, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the...
|
sp1946 |
| ONX |
Onxeo 2019
Onxeo to Present Data supporting Lead Asset AsiDNA™in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting The full press release in PDF Paris (France)...
|
sp1946 |
| ONX |
Onxeo 2018
Press release Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meet...
|
sp1946 |
| ONX |
Onxeo 2018
Financially, we continued to diversify our resources through the monetization of the Beleodaq royalties for $7.5 million. We also set up a line of equity financing, thereby providing the resourc...
|
sp1946 |
| ONX |
Onxeo 2018
today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at the 2nd DNA Damage Response Therapeutics Summit (DDRTS) to be held January 29-31, 20...
|
sp1946 |
| ONX |
Onxeo 2018
Allemaal een goed en gezond Nieuwjaar.De maand van de waarheid.The identified biomarkers are important components in the design of future studies and will be included as soon as the next phase...
|
sp1946 |
| ARR |
Forum Arrowhead Research geopend
Ts maar dat u het weet:Arrowhead Pharmaceuticals (ARWR) Price Target Raised to $165.00 at Cantor FitzgeraldPosted by ABMN Staff on Dec 17th, 2018 //...
|
sp1946 |
| ONX |
Onxeo 2018
RationeelHet moet niet gekker worden:uniQure N.V. (QURE)NasdaqGS - NasdaqGS Real Time Price. Currency in USDAdd to watchlist33.96+11.16 (+48.93%)As of 11:22AM EST. Market open....
|
sp1946 |
| ONX |
Onxeo 2018
Niet vergeten:UPCOMING EVENTS • BIO-Europe: November 5-7, 2018, Copenhagen (Denmark) ...
|
sp1946 |
| ONX |
Onxeo 2018
Koersvoorspellingen, daar waag ik mij niet aan. Beleggers zijn teleurgesteld geweest in de ontwikkelingen van Livatag en ook in de verloren rechtszaak tegen SpeBio { € 8,6 mln. } en hebben daarna het ...
|
sp1946 |
| ONX |
Onxeo 2018
Deze reactie kan niet waar op dit mooie en spannende bericht. Verdere berichten zijn in aantocht. Daar past geen koersje van nog geen € 0,90 bij. ...
|
sp1946 |
| ONX |
Onxeo 2018
Onxeo Reports Third Quarter Financial Information and Provides Business Update AsiDNA™ clinical development progressing to plan ? First safety and activity results of the phase I DRIIV-1 study ...
|
sp1946 |
| ONX |
Onxeo 2018
Q3 2018 financial informationOctober 25, 2018...
|
sp1946 |